Biogen CEO Viehbacher undaunted by Lilly's impending Alzheimer's therapy,...
NEW YORK — Facing a challenging launch for the Alzheimer’s drug Leqembi, Biogen CEO Chris Viehbacher said he would welcome competition from other companies, including Eli Lilly, which is aiming for an...
View ArticleBristol Myers wins accelerated approval for another blood cancer for...
Just two months after earning another approval for its blockbuster blood cancer drug Breyanzi, Bristol Myers Squibb can add an accelerated approval to the list, this time in the third-line setting for...
View ArticleClik here to view.
House panel advances bills targeting rare disease, priority review vouchers
WASHINGTON — Lawmakers advanced the reauthorization of an FDA program designed to stimulate the development of treatments for pediatric rare diseases, despite some opposition from Democrat lawmakers....
View ArticleBain, Atlas, RTW back new biotech developing obesity drugs with $400M
A new obesity biotech has entered the field — and it has $400 million from well-known life sciences investors to test investigational GLP-1 and GIP candidates licensed from Jiangsu Hengrui...
View ArticleRoche was in 'advanced' talks to out-license its Angelman syndrome drug, but...
Roche is back to square one for finding a partner to carry forward its culled Angelman syndrome drug. Last June, the Swiss pharma had started a search for a partner after stopping clinical testing of...
View ArticlePharma is rethinking how it interacts with patients after Eli Lilly ripped up...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) More pharma companies are considering taking a tip from Eli Lilly and offering their drugs directly to...
View ArticleGSK plans to sell off remaining stake in consumer spinout Haleon
British drugmaker GSK will sell off the rest of its share in Haleon after slowly selling off multibillion-dollar pieces of its ownership in the consumer company. The sale of the final 4.2% stake in...
View ArticleClik here to view.
FDA approves Amgen’s T cell engager in aggressive form of lung cancer
The FDA on Thursday granted accelerated approval to Amgen’s bispecific T cell engager tarlatamab in small cell lung cancer, an aggressive disease that makes up roughly 10% to 15% of lung cancer cases....
View ArticleClik here to view.
Jim Burns reunites with Genzyme colleague at Ensoma; Lilly exec to retire...
Jim Burns Jim Burns was looking for his next post after his latest venture in biotech, a gene therapy startup known as Locanabio, shut down “due to the time and capital required to deliver clinical...
View ArticleClik here to view.
Bayer details data from two Phase 3 trial wins for menopause symptom drug
Bayer shared more data on its menopause symptom drug elinzanetant, which demonstrates how the treatment triumphed over placebo in two of three Phase 3 trials. In the placebo-controlled OASIS 1 trial,...
View ArticleErasca revamps pipeline, laying off staff as it licenses cancer drugs from...
Erasca is looking for a refresh as it drops several early-stage cancer assets, picks up new ones from China and raises cash to help push its lead candidate to the finish line. The San Diego biotech...
View ArticleClik here to view.
Australian radiopharma Telix launches bid for Nasdaq listing
Telix Pharmaceuticals, a radiopharma drug and diagnostics maker, has started its march toward a listing on the Nasdaq, submitting its initial pitch to the SEC. The Melbourne-based biotech, which is...
View ArticleQ&A: FTC’s top healthcare enforcer on pharma M&A, company growth and PBMs
The Federal Trade Commission has loomed large over M&A in the biopharma industry in the last two years. The antitrust regulator attempted to block Amgen’s $27.8 billion takeover of Horizon, stopped...
View ArticleClik here to view.
FDA rejects liver cancer drug combo, shares of Korean biotech tank
Korean biotech HLB and its China-based partner Jiangsu Hengrui Pharmaceuticals said Friday that the FDA rejected their drug combination for the most common form of liver cancer. The FDA rejected the...
View ArticleEMA's safety committee recommends suspending preterm birth drugs
The European Medicines Agency is taking aim at preterm birth drugs, with the agency’s safety committee recommending that medicines containing 17-hydroxyprogesterone caproate, also known as 17-OHPC, be...
View ArticleModerna scores European victory over Pfizer and BioNTech in mRNA patent battle
The European Patent Office on Thursday handed a win to Moderna in a long-running patent battle with Pfizer and BioNTech over certain components of the mRNA vaccines authorized to fight Covid-19. “We...
View ArticleClik here to view.
Study identifies groups of people who mistrust the FDA
The FDA has work to do to earn the confidence of certain groups of people who do not trust the agency, a study published Friday by researchers at Harvard Medical School and the University of Colorado...
View ArticleClik here to view.
Rapport, a clinical-stage neuroscience biotech, files for IPO
Rapport Therapeutics, which emerged out of Johnson & Johnson’s neuroscience unit last year, has submitted its pitch for a Nasdaq listing. The Boston-based startup plans to trade as “RAPP” and...
View ArticleMega startup watch; Interview with Siddhartha Mukherjee; Tracking Wegovy’s...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleFDA withdraws Helsinn’s accelerated approval for cancer drug after company’s...
The FDA on Friday withdrew an accelerated approval for Helsinn’s bile duct cancer drug, two years after the company couldn’t complete its confirmatory trial and requested that the FDA withdraw...
View Article